Marucci MA, Lechner DW, Tafuto BA. Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. GIT [Internet]. 2024 Mar. 12 [cited 2024 May 17];2(1). Available from: https://www.hksmp.com/journals/git/article/view/482